New treatments that target tau, a neuronal scaffolding protein that accumulates in neurodegenerative diseases, are entering human clinical trials. Increasingly, clinical trials of such tau directed therapies are focusing on pure 4 microtubule binding repeat (4R) tauopathies (4RT) including corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP). We previously designed the 4RT Neuroimaging Initiative (4RTNI) to develop biomarkers of disease progression to support clinical trials of tau directed therapies in 4RT. During the first four and one half years of the project, we exceeded our planned enrollment, developed structural MRI biomarkers of disease progression, and determined that CSF neurofilament light chain (NfL) levels are correlated with disease progression. We validated our findings in a large international clinical trial in PSP that we designed and led. Based on these studies, we identified two major knowledge gaps that must be addressed prior to future trials: 1) a need for better pharmacodynamic biomarkers that can demonstrate the expected biological effects of treatments (including target engagement); and 2) patients need to be diagnosed at earlier stages of disease to give therapies the best chance of demonstrating efficacy. This competitive renewal will address these gaps by taking advantage of three recent scientific advances: the development of the new tau PET ligand 18F AV1451, new diagnostic criteria for an early form of 4RT called oligosymptomatic PSP (oPSP), predicted to allow diagnosis 2-3 years earlier than current criteria, and the recognition of retinal nerve cel damage in PSP. We will focus efforts on characterizing progression of insoluble tau deposition in 4RT, particularly in oPSP cases. We will recruit 55 CBD, 55 PSP and 60 oPSP participants and 60 age- matched controls, and study each for one or two (oPSP, controls) years using clinical rating scales, 18F AV1451 tau PET scans, 3T MRI scans, new non-invasive ophthalmologic neuronal injury assessments and CSF biomarkers. Individuals will undergo longitudinal clinical and MRI evaluations at baseline, 6, 12, and 24 months, with annual PET and CSF measurements, at five leading 4RT research centers (UCSF, UCSD, Harvard, U. Toronto, and U. Pennsylvania) with a strong track record of collaboration and supported by a new rare disease clinical research consortium called Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL).
We aim to: 1) Determine the natural history of brain insoluble tau deposition as measured by 18F AV1451 uptake on PET scans in 4RT as compared to controls. 2) Quantify longitudinal changes in retinal thickness and vertical saccade gain as measured by optical coherence tomography and infrared oculography. 3) Quantify longitudinal changes in CSF NfL levels compared to other fluid biomarkers. 4) Determine the clinical, MR imaging and neuronal injury marker correlates of 18F AV1451 uptake. Achieving these aims would enable us to intervene earlier in the course of 4RT disease and design more rigorous clinical trials of tau lowering drugs. All data will eventually be made available for use y other researchers.

Public Health Relevance

New drugs that target tau, a neuronal protein that is dysfunctional and accumulates in Alzheimer's disease (AD), corticobasal degeneration (CBD), and progressive supranuclear palsy (PSP), are entering human clinical trials; however, the best methods for assessing whether these drugs are effective have not yet been established. This project will study the four repeat (4R) tauopathies, CBD and PSP, because there are no effective treatments for these disorders and they are more likely to respond to tau-directed therapies than AD. The data generated from this project will allow researchers to design better clinical trials to test the efficacy of new tau-directed drugs in humans.

National Institute of Health (NIH)
National Institute on Aging (NIA)
Research Project (R01)
Project #
Application #
Study Section
Clinical Neuroscience and Neurodegeneration Study Section (CNN)
Program Officer
Hsiao, John
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Francisco
Schools of Medicine
San Francisco
United States
Zip Code
Tsai, Richard M; Lobach, Iryna; Bang, Jee et al. (2016) Clinical correlates of longitudinal brain atrophy in progressive supranuclear palsy. Parkinsonism Relat Disord 28:29-35
Rojas, Julio C; Karydas, Anna; Bang, Jee et al. (2016) Plasma neurofilament light chain predicts progression in progressive supranuclear palsy. Ann Clin Transl Neurol 3:216-25
Rojas, Julio C; Boxer, Adam L (2016) Neurodegenerative disease in 2015: Targeting tauopathies for therapeutic translation. Nat Rev Neurol 12:74-6
Jaeger, Philipp A; Lucin, Kurt M; Britschgi, Markus et al. (2016) Erratum to: Network-driven plasma proteomics expose molecular changes in the Alzheimer's brain. Mol Neurodegener 11:42
Bertoux, Maxime; Sarazin, Marie; Pasquier, Florence et al. (2016) Cognition and neuropsychiatry in behavioral variant frontotemporal dementia by disease stage. Neurology 87:1523
Bang, Jee; Lobach, Iryna V; Lang, Anthony E et al. (2016) Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials. Parkinsonism Relat Disord 28:41-8
Ranasinghe, Kamalini G; Rankin, Katherine P; Lobach, Iryna V et al. (2016) Cognition and neuropsychiatry in behavioral variant frontotemporal dementia by disease stage. Neurology 86:600-10
Walsh, Christine M; Ruoff, Leslie; Varbel, Jonathan et al. (2016) Rest-activity rhythm disruption in progressive supranuclear palsy. Sleep Med 22:50-6
Miller, Zachary A; Sturm, Virginia E; Camsari, Gamze Balci et al. (2016) Increased prevalence of autoimmune disease within C9 and FTD/MND cohorts: Completing the picture. Neurol Neuroimmunol Neuroinflamm 3:e301
Jaeger, Philipp A; Lucin, Kurt M; Britschgi, Markus et al. (2016) Network-driven plasma proteomics expose molecular changes in the Alzheimer's brain. Mol Neurodegener 11:31

Showing the most recent 10 out of 73 publications